VaxInnate, a Cranbury, N.J., vaccine-focused biotech, received a $597,000 small-business innovation grant from the NIH to support work on a vaccine against Dengue fever, a mosquito-borne viral disease. VaxInnate's primary focus is on new influenza vaccines that are designed to stimulate "toll-like receptors" that can produce a more robust immune response. The company's description of its technology is here.